vs
Side-by-side financial comparison of CHAMPIONS ONCOLOGY, INC. (CSBR) and Zeo Energy Corp. (ZEO). Click either name above to swap in a different company.
Zeo Energy Corp. is the larger business by last-quarter revenue ($18.6M vs $15.0M, roughly 1.2× CHAMPIONS ONCOLOGY, INC.). CHAMPIONS ONCOLOGY, INC. runs the higher net margin — 1.8% vs -10.8%, a 12.6% gap on every dollar of revenue. On growth, CHAMPIONS ONCOLOGY, INC. posted the faster year-over-year revenue change (11.5% vs -0.4%). Zeo Energy Corp. produced more free cash flow last quarter ($2.3M vs $-2.0M). Over the past eight quarters, CHAMPIONS ONCOLOGY, INC.'s revenue compounded faster (11.8% CAGR vs -4.0%).
Champions Oncology is an American technology company that develops mouse avatars. Called TumorGrafts, they are used to test a panel of chemotherapy regimens, targeted therapies and monoclonal antibodies to identify potential therapeutic options for cancer patients. The company was founded in 2007 by David Sidransky, M.D., a Johns Hopkins University oncologist.
CSBR vs ZEO — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $15.0M | $18.6M |
| Net Profit | $268.0K | $-2.0M |
| Gross Margin | 51.7% | — |
| Operating Margin | 1.2% | -11.8% |
| Net Margin | 1.8% | -10.8% |
| Revenue YoY | 11.5% | -0.4% |
| Net Profit YoY | -63.2% | -360.9% |
| EPS (diluted) | $0.02 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $15.0M | $18.6M | ||
| Q3 25 | $14.0M | $23.9M | ||
| Q2 25 | $12.4M | $18.1M | ||
| Q1 25 | $17.0M | $8.8M | ||
| Q4 24 | $13.5M | $18.6M | ||
| Q3 24 | $14.1M | $19.7M | ||
| Q2 24 | $14.0M | $14.8M | ||
| Q1 24 | $12.0M | $20.1M |
| Q4 25 | $268.0K | $-2.0M | ||
| Q3 25 | $-436.0K | $-3.2M | ||
| Q2 25 | $-1.8M | $-2.4M | ||
| Q1 25 | $4.5M | $-6.4M | ||
| Q4 24 | $728.0K | $-435.3K | ||
| Q3 24 | $1.3M | $-424.3K | ||
| Q2 24 | $-109.0K | $-277.8K | ||
| Q1 24 | $-2.5M | $-1.5M |
| Q4 25 | 51.7% | — | ||
| Q3 25 | 42.9% | 57.9% | ||
| Q2 25 | 41.1% | 59.8% | ||
| Q1 25 | 61.2% | 99.3% | ||
| Q4 24 | 44.9% | — | ||
| Q3 24 | 49.7% | 50.2% | ||
| Q2 24 | 48.2% | 52.3% | ||
| Q1 24 | 34.7% | — |
| Q4 25 | 1.2% | -11.8% | ||
| Q3 25 | -3.8% | -8.3% | ||
| Q2 25 | -16.2% | -15.8% | ||
| Q1 25 | 26.4% | -153.8% | ||
| Q4 24 | 5.4% | -6.0% | ||
| Q3 24 | 9.5% | -15.2% | ||
| Q2 24 | -1.9% | -18.0% | ||
| Q1 24 | -21.4% | -20.1% |
| Q4 25 | 1.8% | -10.8% | ||
| Q3 25 | -3.1% | -13.5% | ||
| Q2 25 | -14.9% | -13.3% | ||
| Q1 25 | 26.4% | -72.4% | ||
| Q4 24 | 5.4% | -2.3% | ||
| Q3 24 | 9.3% | -2.2% | ||
| Q2 24 | -0.8% | -1.9% | ||
| Q1 24 | -21.1% | -7.6% |
| Q4 25 | $0.02 | — | ||
| Q3 25 | $-0.03 | — | ||
| Q2 25 | $-0.12 | — | ||
| Q1 25 | $0.31 | $-0.48 | ||
| Q4 24 | $0.05 | $1.11 | ||
| Q3 24 | $0.09 | $-0.08 | ||
| Q2 24 | $-0.01 | $0.03 | ||
| Q1 24 | $-0.19 | $-1.54 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $8.5M | $6.1M |
| Total DebtLower is stronger | — | $79.1K |
| Stockholders' EquityBook value | $4.2M | $5.3M |
| Total Assets | $30.2M | $56.9M |
| Debt / EquityLower = less leverage | — | 0.01× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $8.5M | $6.1M | ||
| Q3 25 | $10.3M | $3.9M | ||
| Q2 25 | $9.8M | $68.7K | ||
| Q1 25 | $3.2M | $2.9M | ||
| Q4 24 | $2.8M | $5.6M | ||
| Q3 24 | $2.9M | $4.3M | ||
| Q2 24 | $2.6M | $5.3M | ||
| Q1 24 | $4.5M | — |
| Q4 25 | — | $79.1K | ||
| Q3 25 | — | $84.6K | ||
| Q2 25 | — | $642.8K | ||
| Q1 25 | — | $715.4K | ||
| Q4 24 | — | $787.7K | ||
| Q3 24 | — | $858.6K | ||
| Q2 24 | — | $1.6M | ||
| Q1 24 | — | $748.8K |
| Q4 25 | $4.2M | $5.3M | ||
| Q3 25 | $3.5M | $-1.7M | ||
| Q2 25 | $3.8M | $-59.4M | ||
| Q1 25 | $5.5M | $-23.1M | ||
| Q4 24 | $681.0K | $-88.9M | ||
| Q3 24 | $-332.0K | $-39.3M | ||
| Q2 24 | $-1.9M | $-53.0M | ||
| Q1 24 | $-2.1M | $-173.0M |
| Q4 25 | $30.2M | $56.9M | ||
| Q3 25 | $30.5M | $58.5M | ||
| Q2 25 | $32.3M | $46.2M | ||
| Q1 25 | $30.6M | $47.4M | ||
| Q4 24 | $25.2M | $61.0M | ||
| Q3 24 | $24.9M | $47.1M | ||
| Q2 24 | $26.1M | $49.1M | ||
| Q1 24 | $26.8M | $50.1M |
| Q4 25 | — | 0.01× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.7M | $2.4M |
| Free Cash FlowOCF − Capex | $-2.0M | $2.3M |
| FCF MarginFCF / Revenue | -13.1% | 12.2% |
| Capex IntensityCapex / Revenue | 1.6% | 0.9% |
| Cash ConversionOCF / Net Profit | -6.47× | — |
| TTM Free Cash FlowTrailing 4 quarters | $5.6M | $-9.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.7M | $2.4M | ||
| Q3 25 | $600.0K | $-6.6M | ||
| Q2 25 | $6.9M | $-2.3M | ||
| Q1 25 | $490.0K | $-2.3M | ||
| Q4 24 | $-283.0K | $3.5M | ||
| Q3 24 | $311.0K | $162.2K | ||
| Q2 24 | $-1.8M | $-2.2M | ||
| Q1 24 | $-919.0K | $-10.2M |
| Q4 25 | $-2.0M | $2.3M | ||
| Q3 25 | $554.0K | $-6.8M | ||
| Q2 25 | $6.6M | $-2.7M | ||
| Q1 25 | $448.0K | $-2.6M | ||
| Q4 24 | $-377.0K | $3.4M | ||
| Q3 24 | — | $116.5K | ||
| Q2 24 | $-1.8M | $-2.3M | ||
| Q1 24 | $-1.0M | $-10.4M |
| Q4 25 | -13.1% | 12.2% | ||
| Q3 25 | 4.0% | -28.6% | ||
| Q2 25 | 53.5% | -15.0% | ||
| Q1 25 | 2.6% | -30.0% | ||
| Q4 24 | -2.8% | 18.2% | ||
| Q3 24 | — | 0.6% | ||
| Q2 24 | -13.0% | -15.6% | ||
| Q1 24 | -8.4% | -51.5% |
| Q4 25 | 1.6% | 0.9% | ||
| Q3 25 | 0.3% | 1.0% | ||
| Q2 25 | 2.0% | 2.4% | ||
| Q1 25 | 0.2% | 4.2% | ||
| Q4 24 | 0.7% | 0.5% | ||
| Q3 24 | 0.0% | 0.2% | ||
| Q2 24 | 0.0% | 0.7% | ||
| Q1 24 | 0.8% | 1.1% |
| Q4 25 | -6.47× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.11× | — | ||
| Q4 24 | -0.39× | — | ||
| Q3 24 | 0.24× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CSBR
| Pharmacology Services | $14.5M | 97% |
| Other | $520.0K | 3% |
ZEO
| Nonrelated Party | $18.1M | 98% |
| Related Party | $432.1K | 2% |
